# Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma

> **NCT04526080** · PHASE2 · WITHDRAWN · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** TheraBionic Device
- **DEVICE:** Placebo Device

## Key facts

- **NCT ID:** NCT04526080
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This application needs further attention in terms of FDA approval and will be reassigned under a different trial number later.
- **Last updated:** 2021-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526080, "Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04526080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*